Literature DB >> 29983343

Fruquintinib for previously treated metastatic colorectal cancer.

Talha Khan Burki.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29983343     DOI: 10.1016/S1470-2045(18)30503-5

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  5 in total

1.  Studies of the Efficacy of Low-Dose Apatinib Monotherapy as Third-Line Treatment in Patients with Metastatic Colorectal Cancer and Apatinib's Novel Anticancer Effect by Inhibiting Tumor-Derived Exosome Secretion.

Authors:  Lingying Zhao; Qiang Yu; Chunyi Gao; Jingzhou Xiang; Bowen Zheng; Yujie Feng; Runyang Li; Wenqing Zhang; Xiaoting Hong; Yan-Yan Zhan; Li Xiao; Tianhui Hu
Journal:  Cancers (Basel)       Date:  2022-05-19       Impact factor: 6.575

2.  Validated UPLC-MS/MS method for quantification of fruquintinib in rat plasma and its application to pharmacokinetic study.

Authors:  Yi-Bin Mei; Shun-Bin Luo; Ling-Yan Ye; Qiang Zhang; Jing Guo; Xiang-Jun Qiu; Sai-Li Xie
Journal:  Drug Des Devel Ther       Date:  2019-08-15       Impact factor: 4.162

3.  Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer.

Authors:  Ying Zhang; Jia-Yun Zou; Zhe Wang; Ying Wang
Journal:  Cancer Manag Res       Date:  2019-08-16       Impact factor: 3.989

4.  Fruquintinib inhibits VEGF/VEGFR2 axis of choroidal endothelial cells and M1-type macrophages to protect against mouse laser-induced choroidal neovascularization.

Authors:  Xiaojuan Liu; Aisong Guo; Yuanyuan Tu; Wendie Li; Lele Li; Wangrui Liu; Yuanyuan Ju; Yamei Zhou; Aimin Sang; Manhui Zhu
Journal:  Cell Death Dis       Date:  2020-11-27       Impact factor: 8.469

Review 5.  Emerging Therapeutic Agents for Colorectal Cancer.

Authors:  Marianna Nalli; Michela Puxeddu; Giuseppe La Regina; Stefano Gianni; Romano Silvestri
Journal:  Molecules       Date:  2021-12-09       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.